Harrow, Inc. APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
Harrow, Inc. (HROW) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of -$48.79 thousand for the 3-month period ending 2013-09-30, per its 10-Q filed 2013-11-06.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2014-03-28
- Harrow, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2013-09-30 was -$48.79K.
- Harrow, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2013-06-30 was $149.81K.
- Harrow, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2012 was $139.44K.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2013-09-30 | -$48.79K 10-Q · filed 2013-11-06 | $101.02K derived: sum of 2 quarters · filed 2013-11-06 | $143.55K 10-Q · filed 2013-11-06 | |
| 2013-06-30 | $149.81K 10-Q · filed 2013-08-14 | $192.34K 10-Q · filed 2013-08-14 | ||
| 2012-12-31 | $139.44K 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |